The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 08, 2019

Filed:

Jul. 21, 2015
Applicants:

Novartis Ag, Basel, CH;

The Trustees of the University of Pennsylvania, Philadelphia, PA (US);

Inventors:

Jennifer Brogdon, Cambridge, MA (US);

Eugene Choi, Cambridge, MA (US);

Hilmar Erhard Ebersbach, Basel, CH;

David Glass, Cambridge, MA (US);

Heather Huet, Cambridge, MA (US);

Carl H. June, Merion Station, PA (US);

Joan Mannick, Cambridge, MA (US);

Michael C. Milone, Cherry Hill, NJ (US);

Leon Murphy, Cambridge, MA (US);

Gabriela Plesa, Blue Bell, PA (US);

Celeste Richardson, Cambridge, MA (US);

Marco Ruella, Philadelphia, PA (US);

Reshma Singh, Cambridge, MA (US);

Yongqiang Wang, Shanghai, CN;

Qilong Wu, Shanghai, CN;

Assignees:

Novartis AG, Basel, CH;

The Trustees of the University of Pennsylvania, Philadelphia, PA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/04 (2006.01); C12N 15/63 (2006.01); C12N 5/00 (2006.01); C07K 16/28 (2006.01); C07K 14/705 (2006.01); A61K 35/12 (2015.01); A61K 38/17 (2006.01); C07K 14/715 (2006.01); C07K 19/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/705 (2013.01); A61K 35/12 (2013.01); A61K 38/177 (2013.01); C07H 21/04 (2013.01); C07K 16/2878 (2013.01); C12N 5/00 (2013.01); C12N 15/63 (2013.01); A61K 39/395 (2013.01); A61P 35/00 (2018.01); C07K 14/7151 (2013.01); C07K 16/28 (2013.01); C07K 19/00 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01);
Abstract

The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.


Find Patent Forward Citations

Loading…